Search Results for "Plan B"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Plan B. Results 31 to 40 of 40 total matches.
See also: levonorgestrel

Darunavir (Prezista) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006  (Issue 1243)
treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials ...
Darunavir (Prezista - Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency virus (HIV) infection in previously treated adults. It is coadministered with low-dose ritonavir (Norvir), which increases its bioavailability.
Med Lett Drugs Ther. 2006 Sep 11;48(1243):74-5 |  Show IntroductionHide Introduction

Acupuncture

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
; each session costs about $60-$150 in the US. A few major health insurance plans, including Workers ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Med Lett Drugs Ther. 2006 May 8;48(1234):38-9 |  Show IntroductionHide Introduction

Oral Semaglutide (Rybelsus) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019  (Issue 1583)
with semaglutide than with sitagliptin (58% vs 25%). 17. B Zinman et al. Diabetes Care 2019 Sep 17 (epub). 167 ...
An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-8 |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
once4 EContra One-Step (Afaxys) My Way (Lupin) New Day (Northstar) Option 2 (Perrigo) Plan B One ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1,2 ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
, cefazolin3,7 2 g IV4 laparoscopic hysterectomy anaerobes, Gp B strep, OR cefoxitin or cefotetan3,7 2 g IV ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
hours; it is typically prescribed b.i.d. or t.i.d.. Roughly 80-90% of PTU in the serum is protein ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
to suppress the wake drive by competitively inhibiting orexin A and B from binding to their receptors, OX1R ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a |  Show IntroductionHide Introduction

Drugs for Smoking Cessation

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
smoking over 2 weeks before a planned quit date) to result in abstinence at 4 weeks (49.0% vs 39.2 ...
Smoking tobacco remains the primary preventable cause of death in the US. Smoking cessation often requires both pharmacotherapy and behavioral support.
Med Lett Drugs Ther. 2019 Jul 15;61(1576):105-10 |  Show IntroductionHide Introduction

Table: Treatments Considered for COVID-19 (Archived) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020  (Issue 1595)
(decrease exposure) B Cao et al. NEJM 20209 Population: hospitalized patients w/ pneumonia, SaO2 94 ...
View the Table: Treatments Considered for COVID-19
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289 |  Show IntroductionHide Introduction